Furthermore, cholinesterase inhibition is a therapeutic strategy for AD79 and there are two such inhibitors in the candidate list with galantamine as an established AD therapeutic80, while neostigmine exhibits poor blood–brain barrier penetrance and is therefore not in clinical use for AD. The gene discussed is BCHE; the disease is Alzheimer disease.